Thousands of lung cancer patients in England are now eligible for a Keytruda® combination life-extending treatment through the Cancer Drugs Fund.
Browsing: Disease Area > Lung
Authors discuss the results of this observational real-world study and how sequencing tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
Find out about Plinabulin, a novel immuno-oncology agent in late-stage clinical trials for the treatment of chemotherapy-induced neutropenia and advanced NSCLC.
Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Scientists have discovered a key molecular player in lung cancer, which could be used to tackle the disease.
The China National Drug Administration have granted rapid approval of Alecensa® as a monotherapy treatment for patients with ALK-positive, advanced non-small cell lung cancer.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.